Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations

NCT06029816 | Unknown Phase 2 DMC

• 2 other identifiers: CVL009-2001Chinadrugtrials
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

Single-arm, open-label, multicenter phase II clinical study

Conditions

NSCLC

Keywords

NSCLC; EGFR; Neratinib tablets

Outcome Measures

Primary Outcomes (1)

• IRC-assessed objective response rate (ORR)

  IRC-assessed objective response rate (ORR)

  Through study completion, an average of 1 year

Other Outcomes (2)

• ORR by investigator

  Through study completion, an average of 1 year

• Overall Survival (OS)

  Through study completion, an average of 1 year

Study Arms (3)

Arm1-Exon 18

EXPERIMENTAL

Exon 18 G719X, E709X, etc，Up to 14 patients will be enrolled in this group and will be treated with neratinib tablets in 28-day cycles，

Drug: Neratinib tablets

Arm2-Exon 20

EXPERIMENTAL

S768I in exon 20，Up to 14 patients will be enrolled in this group and will be treated with neratinib tablets in 28-day cycles，

Drug: Neratinib tablets

Arm3-Exon 21

EXPERIMENTAL

L861Q of exon 21，Up to 14 patients will be enrolled in this group and will be treated with neratinib tablets in 28-day cycles，

Drug: Neratinib tablets

Interventions

Neratinib tablets DRUG

Neratinib tablets

Also known as: Epilepsy

Arm1-Exon 18; Arm2-Exon 20; Arm3-Exon 21

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years;
• Histologically or cytologically confirmed non-small cell lung cancer, stage IIIB or IV according to IASLC 2009;
• Tissue or blood samples are confirmed by the central laboratory or research center as rare EGFR mutations, including exon 18 G719X, E709X, etc., S768I in exon 20 and at least one of the L861Q mutations in exon 21;
• Ineffective or intolerant to standard treatment regimens, and disease progression after treatment;
• The number of previous chemotherapy regimens does not exceed 2 (a. replacement of platinum drugs for drug toxicity reasons is counted as a regimen; b. postoperative adjuvant chemotherapy, from the end of treatment to recurrence \> 6 months is not counted as a previous chemotherapy regimen);
• ECOG standard score 0-1;
• Predicted survival ≥ 12 weeks;
• Presence of measurable lesions according to RECIST 1.1: At least one lesion that is not irradiated, ≥ 10 mm in long diameter (lymph node lesions need to be ≥ 15 mm in short diameter), and can be accurately measured at baseline and can be repeatedly measured under CT or MRI; If the subject only has post-radiotherapy lesion, and this lesion has been confirmed as imaging progression and can be measured, it can be selected as target lesion (except for brain lesion), and brain lesion is not included as measurable target lesion;
• Subjects with asymptomatic brain metastases or brain metastases can be included in this study when the following conditions are met: brain metastases are treated and stable, such as clinical examination and brain scan (MRI or CT scan) confirmed at least 4 no evidence of lesion progression during the screening period, no neurological symptoms and no need for corticosteroid therapy. If the subject has brain metastases that have been treated surgically or with radiation, a time window of ≥ 4 weeks is required before the first dose of nelatidine tablets to ensure that adverse events associated with radiation or surgical treatment have decreased to ≤ Grade 1;
• Bone marrow reserve or organ function needs to meet the following laboratory value criteria:
• Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
• Platelet count (PLT) ≥ 90 × 109/L
• Hemoglobin (Hb) ≥ 90 g/L
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; ≤ 5 × ULN in the presence of liver metastases
• Serum total bilirubin (TBIL) ≤ 1.5 × ULN

You may not qualify if:

• Received any of the following treatments: 1. previous treatment with any EGFR tyrosine kinase inhibitor; 2. major surgery 4 times before the first dose of the study drug; c. 4 times before the first dose of the study drug, more than 30% of bone marrow irradiation, or extensive radiotherapy; d. within 7 days before the first dose of the study drug, the use of CYP3A4 strong inhibitors, inducers or drugs that are CYP3A4 sensitive substrates with a narrow therapeutic window;
• Patients with other malignant tumors and need standard treatment or major surgery within 2 years after the first dose of study treatment;
• In the beginning of the study treatment, there are greater than CTCAE grade 1 failed to alleviate the residual toxicity of previous treatment, except alopecia and previous chemotherapy-induced grade 2 neurotoxicity;
• Spinal cord compression or brain metastasis, unless asymptomatic, stable condition, and not requiring steroid therapy for at least 2 weeks before the first dose of study treatment;
• Poor blood pressure control after drug treatment (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg);
• Patients with severe or uncontrollable systemic diseases, including gastrointestinal ulcers and bleeding and other diseases;
• There are many factors that affect the oral administration of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction and other gastrointestinal diseases or abnormalities);
• ECG: QTcF: female \> 470 ms, male \> 450 ms;
• Echocardiography: score (LVEF) ≤ 50%;
• History of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy or any evidence of clinically active interstitial lung disease;
• History of immunodeficiency, including HIV test positive, active hepatitis B/C (HBV-DNA \> 1000 IU/mL or \> 2500 copies/mL, HCV-RNA ≥ 10 ³ copies/mL) or suffering from other acquired, congenital immunodeficiency diseases, or history of organ transplantation;
• Women who are lactating or have a positive pregnancy test result before the first dose of study treatment;
• Participated in any other drug clinical study before the first dose;
• The investigator judges that there are any patients who endanger the patient's safety, interfere with the study assessment, and have poor compliance;

Sponsors & Collaborators

• Convalife (Shanghai) Co., Ltd.: lead

Study Sites (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

Location

MeSH Terms

Interventions

neratinib

Study Officials

• Wenfeng Fang

  Sun Yat-sen University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Qiong Wang

CONTACT

（021）6877 3638; qiong.wang@convalife.com

Dong Wang

CONTACT

（021）6877 3638; dong.wang@convalife.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Fourteen patients each had three mutation sites and 42 patients were co-enrolled

Study Record Dates

• First Submitted: July 31, 2023
• First Posted: September 8, 2023
• Study Start: November 20, 2023
• Primary Completion: December 30, 2024
• Study Completion: December 30, 2025
• Last Updated: September 8, 2023

Record last verified: 2023-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)